Press "Enter" to skip to content

Collaborative research program of OMRON Healthcare and Kyoto University "Healthcare Medical AI" to prevent cardiovascular disease events with AI and home measurement data

KYOTO, Japan June 24, 2021 / PRNewswire / – OMRON Healthcare Co., Ltd. (Head Office: Muko-city, Kyoto, Japan President and CEO: Isao Ogino ) and Kyoto University (Sakyo-ku, Kyoto -city Kyoto, Japan President: Nagahiro Minato) announced today a new Collaborative Research Program called "Health Medical AI" (Principal Investigator: Yasushi Okuno Ph.D., Prof., Department of Biomedical Data Intelligence, Faculty of Medicine, Kyoto University ) to use artificial intelligence (AI) and an innovative conj collection of data from home measurements to prevent cardiovascular disease events.

[1 9459001]

 Takehiro Hamaguchi, Senior General Manager, Technology Development Headquarters, OMRON Healthcare Co., Ltd. (pictured left) and Yasushi Okuno, Ph.D ., Prof., Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan (pictured right) "src =" "data-src = " /vJu1Deph9qmhtgXsgurhmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MC41ODc1/ aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24- / https: // 73fd5836e03719d081bd3770678d7b49 "/> <noscript> <img

Takehiro Hamaguchi, Senior General Manager, Technology Development Headquarters, OMRON Healthcare Co., Ltd. (pictured left) and Yasushi Okuno, Ph.D., Prof., Department of Data Intelligence Biomedical, Faculty of Medicine, Kyoto University, Kyoto, Japan (pictured right)

The first study in the Collaborative Research Program Explore how AI can derive new personalized blood pressure improvement methods based on daytime and nighttime blood pressure fluctuation, home electrocardiographic recordings, and data lifestyle. The goal is to further improve the management of high blood pressure. The study will investigate how AI can accurately predict cardiovascular disease at an early stage.

Hypertension is the leading cause of death worldwide * 1 . Since cardiovascular diseases often require long-term nursing care, it is important to prevent events not only because of the life-threatening aspect, but also in light of maintaining quality of life. In Japan approximately 43 million * 2 of people are hypertensive, of which 29% have been treated and their blood pressure values ​​poorly controlled * 3 . To prevent life-threatening events, more solutions need to be developed for patients suffering from hypertension. Even if blood pressure values ​​are properly controlled, there are still chances that patients will develop an event. Therefore, early detection and early intervention in hypertension care should be emphasized so that events can be predicted during daily health management.

The collaboration between Kyoto University and OMRON Healthcare focuses on two research topics: The development of a new method of blood pressure monitoring and blood pressure analysis for early detection of cardiovascular events using AI Regarding the new blood pressure monitoring method, the joint team will use artificial intelligence technology to develop personalized blood pressure monitoring by analyzing biological data sets (body weight, body composition, activity volume and Na ratio. / K * 4 ) and habits (smoking and drinking) on ​​a daily basis. The team will develop a system for detecting abnormal home measurement data for symptoms of cardiovascular events at an early stage. Since events occur unpredictably, early detection of the disease is one of the key challenges. By analyzing changes in various set points of biological data measured at home using AI technology, it will be possible to detect signs of events faster and with greater probability so that treatment can be adjusted, realizing prevention of cardiovascular events.

"OMRON's Going for Zero mission is big and bold, and we can't do it alone. This collaboration with Kyoto University to develop a Groundbreaking research involving Al and cardiovascular disease is another example of how we are partnering with like-minded organizations to improve outcomes and make measurable progress in eliminating heart attacks and strokes, "said OMRON President and CEO. in the USA Ranndy Kellogg .

"Collaboration is an essential, yet underused, tool that opens new doors and ultimately makes patients healthier. Our partnership with Kyoto University is an exciting example of this, combining the OMRON Healthcare's heritage and richness of cardiovascular expertise with the University's expertise in AI research applied to health data. It is through collaborative initiatives like this that we can drive the healthcare industry forward. " added Andre Van Gils OMRON Healthcare Global Sales and Marketing Senior General Manager. "Our recent flagship program, Hypertension Plus with the NHS in the UK and VitalSight in North America demonstrates the feasibility and usability of remote monitoring of patients in daily practice This research program with Kyoto University could stratify ficate programs like these, enabling a new generation of highly personalized preventive care. "

OMRON Healthcare is globally recognized for its Going for Zero mission to eliminate heart attacks and strokes. In the past six years, the company has expanded its business domain from blood pressure measurement to innovative devices including a portable blood pressure monitor and healthcare management services. In the US, UK, and Singapore OMRON has launched new remote patient monitoring services that can be used to measure biological data sets from home and share the data with healthcare professionals. health, supporting them with a better understanding of their patients' health conditions and required treatment plans, contributing to Going for Zero

The program will undoubtedly help us to move forward with Going's vision for Zero of eliminating ular cardiovascular by OMRON's vital detection technology with the help of AI from Kyoto University .


* 1 . [1] GBD 2019 Risk Factors Collaborators, vol. 396, 10258, P1223-1249,[19459008:)[19459002:Comprehensivesurveyoflivingconditionsin2013

* 3 . Guidelines for the treatment of hypertension in 2019

* 4 . Urinary sodium: potassium ratio (Na +: K +)

Yasushi Okuno Ph.D., Prof., Department of Biomedical Data Intelligence, School of Medicine, Kyoto University Kyoto, Japan .
In the midst of the global COVID-19 pandemic and the increased risk of collapse of health systems, one of the urgent challenges is the development of medical systems outside of hospitals. This is directly associated with the problems that we are going to face in the very near future, such as escalating medical costs due to the over-aged society and declining healthcare workers. In this collaborative "healthcare medical AI" research program, we would like to explore the solutions of how to prevent event risks and lead a happier and healthier life at home in collaboration with a new kind of healthcare system and AI studies.

Takehiro Hamaguchi Senior General Manager, Technology Development Headquarters, OMRON Healthcare Co., Ltd.
Cumulative Global Sales of OMRON Healthcare Home Use Blood Pressure Monitors They have reached 300 million units, and are now accessible to people around the world. However, at the same time, there are still many people who have been struggling with managing hypertension and have suffered from serious conditions. We have established the collaborative research program "Healthcare Medical AI" with Kyoto University and will explore the correlation between personal attributes, lifestyle and hypertension, then discover effective ways to improve the condition based in apprenticeships. In addition, we will try to find the most effective system to prevent cardiovascular events with our innovative AI and biological detection technology.

Outline of the collaborative research program "Healthcare Medical AI"

  1. Name of the program: Healthcare Medical AI

  2. Location: Inside the campus of Kyoto University

  3. Period: From June 2021 to March 2024

 Kyoto University "src =" http: // "data-src =" api / res / 1.2 / 8V9sevARjzwrF_V1jK_zGQ - / YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExNi4zMjU-and / / /api/res/1.2/9PP5tiSC14Om0B2VzAu14Q--~B/aD02Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/ / 5eecc1dbbe43e1c>: // s / ny / api / res / 1.2 / 8V9sevARjzwrF_V1jK_zGQ - / YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExNi4zMjU14i/https: //u.u ~ aD02Njt3PTQwMDthcHBpZD15dGFjaHlvbg - / https: // "class =" caas-img "/> </noscript> [194599013008] [1945990138] [1945990138] [1945990138] [1945990138]</p><p><figcaption
class= Kyoto University [1945900Kyoto]

 Cision "src =" "data-src =" 1.2 / IkH7iDlhawbtmpf9cWDwfQ - / YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY- / https: // / https: // / https: // / https: // // / fec582db6d83c1a4d71 "width 16" = 16d83c1a4d71 "width 16" = "16" /> <noscript> <img


See original content to download multimedia: ai-para -prevent-cardiovascular-disease-events-with-ai-and-home-measurement-data-301318976.html

SOURCE OMRON Healthcare, Inc.

Source link

Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *